Biodesix — Third Quarter 2026 Earnings Summary

Biodesix reported third-quarter 2026 total revenue of $24.0 million, representing a 10% year-over-year increase driven by a 24% rise in diagnostic test volumes. The company maintained an 81% gross margin while reducing its net loss to $8.0 million and improving adjusted EBITDA loss by 16% compared to the prior year. Despite the growth, management cited execution challenges including a smaller-than-planned sales force and seasonal factors as reasons for revenue falling short of internal expectations. Consequently, Biodesix revised its full-year 2026 revenue guidance upward to a range of $101 million to $103 million.